In vivo validation of candidate genes regulating efficacy of GBM immunotherapy uses AAV-sgMgat5, Pdia3, Emp1 CD8+ TCR transgenic OT-I mice with cognate cOVA model tumour antigen injected, and conducted anti-tumour activity measurement using survival plots, flow cytometry of T cell infiltration, and tumour luciferase imaging [118]. Here, PDIA3 is linked to neoplasm.